Elemind

Overview

Elemind is a neurotechnology company developing wearable devices that use neuromodulation techniques to shape brainwaves and alter brain states, targeting applications like sleep improvement, Essential Tremor suppression, pain threshold increase, anesthesia augmentation, and memory enhancement.¹²³⁴ The company operates in the electric medicine and sleep tech markets, selling headbands directly to consumers and partnering with academic institutions and health systems for validation and expansion.³⁴ It has raised $12 million in seed funding and reports clinical trial results showing 76% of participants with faster sleep onset.¹³

History

Elemind was founded in 2019 by Meredith Perry (Co-Founder & CEO), Dr. David Wang (Co-Founder & CTO), Dr. Ed Boyden, Dr. Nir Grossman, and Dr. Heather Read, with advisors including Dr. J. Craig Venter.²⁴ The company raised $12 million in a seed funding round.¹ In 2024, it launched its first product, a $349 wearable headband using EEG sensors and bone-conduction sound for sleep induction by suppressing alpha waves.¹ Elemind continues research into broader neuromodulation applications beyond sleep.³⁴

Product Lines

Notable Products

• Elemind Headband - Wearable device tracks brainwaves via EEG and delivers bone-conduction sound bursts to suppress alpha waves for sleep induction.
• Essential Tremor Suppression Device - Neuromodulation technology applied to suppress symptoms of Essential Tremor.
• Pain Threshold Device - Wearable neuromodulation to increase pain thresholds.
• Memory Formation Booster - Technology to boost memory formation through brainwave modulation.
• Anesthesia Augmentation Device - Neuromodulation to augment anesthesia effects.

Reputation

Elemind is recognized by professionals for its innovative drug-free neuromodulation approach, backed by MIT-affiliated founders and clinical trial data showing 76% sleep improvement rates.¹³⁴ Enthusiasts in sleep tech praise its real-time brain response capabilities and potential across medical uses.³⁴ Limited product availability and early-stage status lead to some skepticism on long-term efficacy among critics.¹